Analyst Price Target is $3.00
▼ -27.18% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Virios Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a -27.18% upside from the last price of $4.12.
Current Consensus is
Moderate Buy
The current consensus among 2 contributing investment analysts is to moderate buy stock in Virios Therapeutics. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Read More